Drug or treatment

Ublituximab clinical trials

• 12Clinical trials
• 10Countries

Newest trials

All recruiting trials (12)

• Ublituximab in people with schizophrenia

  This study tests whether ublituximab can help reduce symptoms in adults with treatment‑resistant schizophrenia who are already taking standard antipsychotic therapy.

  Recruiting at 2 sites Phase 2 TG Therapeutics, Inc. · Little Rock, Arkansas and 1 other locations · NCT07680946

• Ublituximab maintenance after efgartigimod response in myasthenia gravis

  This study tests whether giving ublituximab as maintenance after a positive response to efgartigimod helps adults with myasthenia gravis.

  Recruiting at 7 sites Phase 2 TG Therapeutics, Inc. · Colorado Springs, Colorado and 6 other locations · NCT07673744

• Ublituximab in MS: how injection site and delivery method affect absorption

  This study tests how different SC injection sites and a prefilled pen delivery compare in how ublituximab behaves in the body for people with relapsing MS.

  Recruiting at 44 sites Phase 2 TG Therapeutics, Inc. · Bihać and 43 other locations · NCT07503873

• Switching to ublituximab for ocrelizumab wearing-off in multiple sclerosis

  This pilot will try switching people with relapsing MS who experience symptom 'wearing off' on ocrelizumab to ublituximab to see if their symptoms improve or return later.

  Recruiting Phase 4 Johns Hopkins University · Baltimore, Maryland · NCT07389590

• Ublituximab (Briumvi) for early relapsing MS

  This study will test whether giving Ublituximab (Briumvi) about twice a year is safe and changes a blood marker (neurofilament light) in adults with early relapsing MS.

  Recruiting Phase 4 Northwestern University · Chicago, Illinois · NCT07225361

• Ublituximab in Pediatric Relapsing MS: See if a B-cell therapy works in kids

  This study tests whether ublituximab can work in children and teens with relapsing MS and compares it to fingolimod in eligible participants.

  Recruiting at 5 sites Phase 2/3 TG Therapeutics, Inc. · Salt Lake City, Utah and 5 other locations · NCT07220252

• Ublituximab for early, autoantibody‑positive immune‑mediated necrotizing myopathy

  This trial will test whether adding ublituximab to standard immunosuppressive therapy helps adults with early, active anti‑SRP or anti‑HMGCR antibody–positive immune‑mediated necrotizing myopathy improve over 24 weeks.

  Recruiting at 4 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 7 other locations · NCT07103746

• Retinal OCT biomarkers for ublituximab response in relapsing MS

  We will test whether special retinal OCT scans can find signs of immune activity in people with relapsing MS who are starting ublituximab or already on a stable MS medication.

  Recruiting University of Maryland, Baltimore · Baltimore, Maryland · NCT06864936

• Evaluating the safety and effectiveness of ublituximab in older adults with relapsing multiple sclerosis

  This study is testing whether a new medication called ublituximab is safe and effective for older adults aged 55 to 80 with relapsing multiple sclerosis.

  Recruiting Neurology Center of New England P.C. · Foxborough, Massachusetts · NCT06681623

• Ublituximab for walking and motor function in relapsing multiple sclerosis

  This study will test whether ublituximab improves walking, balance, and thinking in people with relapsing‑remitting multiple sclerosis.

  Recruiting Early Phase 1 Georgia State University · Atlanta, Georgia and 1 other locations · NCT06629428

• Evaluating real-world experiences of patients treated with BRIUMVI® for relapsing multiple sclerosis

  This study is looking to see how well BRIUMVI® works and what side effects it has for people with relapsing multiple sclerosis in everyday settings.

  Recruiting at 113 sites TG Therapeutics, Inc. · Birmingham, Alabama and 112 other locations · NCT06433752

• Evaluating a modified treatment regimen of ublituximab for relapsing multiple sclerosis

  This study is testing a new way to use ublituximab to see if it can help people with relapsing multiple sclerosis feel better and stay safe.

  Recruiting at 49 sites Phase 3 TG Therapeutics, Inc. · Birmingham, Alabama and 50 other locations · NCT05877963

Quick answers

How many clinical trials of Ublituximab are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 10 countries. The most sites are in United States (11 trials), Poland (3 trials), Slovakia (1 trial), Puerto Rico (1 trial), United Kingdom (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 4: 2, Phase 2/3: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →